Gelatin sponges (Gelfoam) as a scaffold for osteoblasts.
Gelatine sponge because of its flexibility, biocompatibility, and biodegradability, has the potential to be used as a scaffold to support osteoblasts and to promote bone regeneration in defective areas. This study aimed to determine osteoblast proliferation, differentiation, and integration in modified and un-modified gelatine sponges. Three scaffolds were studied: gelatine sponge (Gelfoam), gelatin sponge/mineral (hydroxyapatite) composite, and gelatin sponge/polymer (poly-lactide-co-glycolide) composite. 2-D plastic coverslip was used as control. The gelatin sponges were modified using PLGA coating and mineral deposition to increase biodegradation resistance and osteoblast proliferation respectively. The scaffolds were characterized using Scanning Electron Microscopy (SEM) and X-ray diffraction. Cell number (DNA content), cell-replication rate (thymidine assay), and cell differentiation (alkaline phosphatase activity) were measured 24 h, 3 days, and 1, 2, 3 weeks after the osteoblast-like cells were cultured onto the scaffolds. Cell penetration into the sponges was determined using haematoxylin-eosin staining. Both modified and unmodified gelatine sponges demonstrated ability to support cell growth and cells were able to penetrate into the sponge pores. In a comparison of different scaffolds, cell number and cell replication were highest in sponge/hydroxyapatite composite and lowest in sponge/PLGA composite.
Rohanizadeh
Ramin
R
Bone and Skin Research Group, Department of Physiology, University of Sydney, Sydney, NSW, Australia. raminr@pharm.usyd.edu.au
Swain
Michael V
MV
Mason
Rebecca S
RS
D002113:Calcification, Physiologic / Q000187:drug effects; D002448:Cell Adhesion / Q000187:drug effects; D002454:Cell Differentiation / Q000187:drug effects; D002465:Cell Movement / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects; D002478:Cells, Cultured; D005781:Gelatin Sponge, Absorbable / Q000737:chemistry / Q000494:pharmacology*; D006801:Humans; D008422:Materials Testing; D010006:Osteoblasts / Q000187:drug effects* / Q000502:physiology; D016062:Porosity; D054457:Tissue Scaffolds / Q000737:chemistry
J Bone Miner Res. 1994 Feb;9(2):161-9
8140929
Proc Natl Acad Sci U S A. 2005 Apr 26;102(17):5953-7
15827122
Biomaterials. 2002 Aug;23(15):3175-81
12102189
J Oral Maxillofac Surg. 1996 Nov;54(11):1282-6
8941177
J Biomed Mater Res B Appl Biomater. 2005 Jul;74(1):468-75
15889421
J Biomed Mater Res. 2001 Oct;57(1):8-14
11416843
Adv Drug Deliv Rev. 2003 Nov 28;55(12):1613-29
14623404
Adv Drug Deliv Rev. 2003 Nov 28;55(12):1547-67
14623401
J Biomed Mater Res. 2000 Aug;51(2):273-9
10825227
Mol Biol Cell. 1999 Mar;10(3):785-98
10069818
J Biol Chem. 2001 Jun 15;276(24):21351-8
11292824
Calcif Tissue Int. 1992 May;50(5):391-6
1596774
Crit Rev Immunol. 1999;19(5-6):389-429
10647744
Crit Rev Food Sci Nutr. 2001 Sep;41(6):481-92
11592686
J Oral Maxillofac Surg. 1992 Jun;50(6):608-12
1593323
J Am Podiatr Med Assoc. 1993 Mar;83(3):123-9
8468693
Biomaterials. 2005 Sep;26(25):5221-30
15792549
Annu Rev Biomed Eng. 2004;6:41-75
15255762
J Thorac Cardiovasc Surg. 2000 Feb;119(2):368-75
10649213
FASEB J. 1992 Sep;6(12):3117-21
1521742
J Appl Biomater. 1991 Fall;2(3):187-208
10149083
Cancer Invest. 1998;16(3):176-82
9541632
Science. 1987 Oct 23;238(4826):491-7
2821619
J Orthop Res. 2003 Jul;21(4):604-9
12798058
Biomaterials. 2005 Aug;26(23):4856-65
15763265
J Biomed Mater Res. 2000 Nov;52(2):246-55
10951362
J Biomed Mater Res. 1998 Dec 15;42(4):626-33
9827688
J Biomed Mater Res. 1998 Winter;43(4):422-7
9855200
J Thorac Cardiovasc Surg. 2001 May;121(5):932-42
11326237
Biomaterials. 2002 Dec;23(24):4765-73
12361615
Int J Pharm. 2001 Jun 19;221(1-2):1-22
11397563
Biochem J. 1960 Apr;75:91-102
14444672